Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 297

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 297
---
,443,500​Pursuant to the Business Combination Agreement, on April 30, 2025, the Mergers were completed (see Note 1). In connection with the completion of the Mergers, the Liminatus unsecured promissory was netted as Iris and Liminatus are now one consolidated entity.​Upon the consummation of the Business Combination, $9,160,000in deferred underwriting fees were settled, of which $7,000,000will be settled in common shares of the combined company upon the earlier of (i)180 daysfrom the consummation of the Business Combination, and (ii) the Company’s next share offering, $500,000was settled in cash and $1,660,000was waived and no longer payable. The remaining $500,000will be settled upon the earlier of the consummation of the combined company’s next share offering, or insix monthsfrom the date of the business combination.​Upon the consummation of the Business Combination, on April 30, 2025, the combined company remitted payment to Benjamin Securities, Inc. in the amount of $500,250in connection with the capital markets advisory agreement.​On May 1, 2025, the Company paid $702,359to the shareholders whom redeemed their shares on March 4, 2025.​​

#### F-76

#### Report of Independent Registered Public Accounting Firm​To the Shareholders and Board of Directors ofIris Acquisition Corp.​Opinion on the Financial Statements​We have audited the accompanying balance sheetsof Iris Acquisition Corp. (the “Company”) as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders’ deficit and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.​Explanatory Paragraph – Going Concern​The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described